TARO PHARMACEUTICAL INDUS (TARO)
IL0010827181 - Common Stock
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TARO, HES, ANSS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries is Now Oversold (TARO)
Kuehn Law Encourages PGTI, TAST, TARO, and ANSS Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro
/PRNewswire/ -- Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for...
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ANSS, TARO, MDC
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Taro Provides Results for December 31, 2023
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TAST, MDC, TARO, SOLO
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Taro to Release Third Quarter Results on January 25, 2024
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TARO, MDC, PGTI, VIA
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Sun Pharma to take Taro private for $43 per share (NYSE:TARO)
Taro Pharmaceutical Industries (TARO) said it has agreed to be taken private by controlling shareholder Sun Pharmaceutical Industries for $43 a share. Read more here.
Taro Announces Merger Agreement with Sun Pharma
/PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or...
Taro Pharmaceutical Industries Enters Oversold Territory (TARO)
TARO Makes Notable Cross Below Critical Moving Average
Taro Pharmaceutical GAAP EPS of $0.23, revenue of $148.2M (NYSE:TARO)
Taro Pharmaceutical press release (NYSE:TARO): Q2 GAAP EPS of $0.23.Revenue of $148.2M (+13.6% Y/Y).Research and development (R&D) expenses of $14.3...
Taro Provides Results for September 30, 2023
Taro to Release Second Quarter Results on October 26, 2023
RSI Alert: Taro Pharmaceutical Industries (TARO) Now Oversold
Taro Pharmaceutical Non-GAAP EPS of $0.40 beats by $0.09, revenue of $158.9M beats by $9.87M (NYSE:TARO)
Taro Pharmaceutical press release (TARO): Q2 Non-GAAP EPS of $0.40 beats by $0.09.Revenue of $158.9M (+1.4% Y/Y) beats by $9.87M.
Taro Provides Results for the Quarter Ended June 30, 2023
Notable Tuesday Option Activity: FIZZ, APLD, TARO
Taro to Release First Quarter Results on July 26, 2023
Krensavage Asset Management Opposes Sun's Lowball Bid for Taro
/PRNewswire/ -- As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Krensavage Asset Management LLC opposes Sun...
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023
Why Shares of Taro Pharmaceutical Are Rising Tuesday
The company is mulling a buyout offer from Sun Pharmaceutical.
Taro Pharmaceutical misses top an bottom line consensus for Q1 (NYSE:TARO)
Taro Pharmaceutical press release (TARO): Q1 GAAP EPS of $0.18 misses by $0.05.Revenue of $146.6M misses by $4.09M.Gross profit of $75.7 million (51.6% of net sales) compared to...
Taro Provides Results for Year Ended March 31, 2023
Taro to Release Full Year Results on May 23, 2023